FOCL (Edap TMS) ROCE %: -77.12% (As of Mar. 2026)

What is Edap TMS ROCE %?

Edap TMS FOCL +1.91% 53 ROCE % is -77.12% as of Mar. 2026. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Edap TMS's annualized ROCE % for the quarter that ended in Mar. 2026 was -77.12%.

Edap TMS (NAS:FOCL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Edap TMS ROCE % Related Terms

Edap TMS ROCE % Historical Data

* Premium members only.

The historical data trend for Edap TMS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edap TMS ROCE % Chart

Edap TMS Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

1.97

-2.72

-28.80

-33.13

-60.92

Edap TMS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-53.15	-63.68	-61.29	-221.00	-77.12

53GF Score

Edap TMS SA FOCL

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Edap TMS ROCE % Calculation

Edap TMS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-28.019	/	( ( (89.407 - 39.28)	+	(78.997 - 37.141) )	/ 2 )
	=	-28.019	/	( (50.127	+	41.856)	/ 2 )
	=	-28.019	/	45.9915
	=	-60.92 %

Edap TMS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-29.464	/	( ( (78.997 - 37.141)	+	(72.059 - 37.508) )	/ 2 )
	=	-29.464	/	( ( 41.856	+	34.551 )	/ 2 )
	=	-29.464	/	38.2035
	=	-77.12 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -77.12% mean?

Edap TMS (FOCL) has a ROCE % of -77.12% as of Mar. 2026.

Is Edap TMS's ROCE % too high?

Edap TMS's current ROCE % is -77.12%. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Edap TMS's ROCE % compare to ACH and YI?

Edap TMS's ROCE % of -77.12% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Distribution company?

The median ROCE % among Medical Distribution companies is 9.22, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current ROCE % is -77.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Edap TMS stock overvalued right now?

Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current ROCE % is -77.12%. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Edap TMS (FOCL), the current ROCE % is -77.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edap TMS (FOCL) Overvalued in 2026?

Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued. The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52. GuruFocus considers Edap TMS to be Modestly Overvalued.

Key valuation signals for FOCL:

ROCE %: -77.12%
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edap TMS Business Description

Industry Healthcare Medical Distribution

Comparable Companies ACH YI COSM HKPD VNOV SNYR MCK COR CAH ASX:SIG HSIC SHSE:601607 HKSE:01099 XSWX:GALE SHSE:600332 SHSE:600998 TSE:7459 OSTO:ASKER MIL:AMP SHSE:600511

Other Exchanges EDA:Germany

Address Parc d\'Activites La Poudrette-Lamartine, 4/6, rue du Dauphine, Vaulx-en-Velin, FRA, 69120

Website http://www.focalone.com

Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.

53GF Score

Get the complete analysis for FOCL

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.08

Price

$4.52

GF Value

View FOCL Analysis

See ROCE % data for all stocks →